CSBio CSBio

X
[{"orgOrder":0,"company":"SeraNovo","sponsor":"Carna Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SeraNovo Enters into a Second License Agreement with Carna Biosciences for Development of Oral Formulation of Carna\u2019s Kinase Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"SeraNovo"},{"orgOrder":0,"company":"Merus","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,660.0 million","upfrontCash":"$40.0 million","newsHeadline":"Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Merus"},{"orgOrder":0,"company":"Synaffix","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"D","amount":"$132.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Synaffix"},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","amount":"$2,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Announces Expansion of ADC Collaboration with MacroGenics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Synaffix"},{"orgOrder":0,"company":"Anavo Therapeutics","sponsor":"MRL Ventures Fund","pharmaFlowCategory":"D","amount":"$30.9 million","upfrontCash":"Undisclosed","newsHeadline":"Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Anavo Therapeutics"},{"orgOrder":0,"company":"Synaffix","sponsor":"ABL Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Synaffix"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, ABL Bio will be responsible for the research, development, and commercialization of bispecific ADCs, designed to overcome the limitations of conventional therapeutic ADCs that target only a single antigen on the targeted cancer cell.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: ABL Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will be used to advance pipeline of novel phosphatase modulators toward the clinic development by leveraging its unique IGNITE phosphatase drug discovery platform.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: MRL Ventures Fund

            Deal Size: $30.9 million Upfront Cash: Undisclosed

            Deal Type: Financing May 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, MacroGenics gained access to Synaffix's clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads, each designed to enable ADCs with best-in-class efficacy and tolerability.

            Lead Product(s): Antibody-drug Conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: MacroGenics

            Deal Size: $2,200.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the licensing agreement, Synaffix will provide access to proprietary Antibody-Drug Conjugate technologies to CKD Pharm, comprising GlycoConnect™, HydraSpace™ and an undisclosed linker-payload from the toxSYN™ platform.

            Lead Product(s): Antibody-drug Conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Chong Kun Dang Pharm

            Deal Size: $132.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Merus will lead discovery and early stage research activities while Loxo Oncology at Lilly will be responsible for additional research, development and commercialization activities.

            Lead Product(s): Bispecific antibody therapies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: $1,660.0 million Upfront Cash: $40.0 million

            Deal Type: Collaboration January 19, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, the companies will expand their existing collaboration and jointly continue to develop an oral formulation with an increased bioavailability.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Carna Bioscience

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY